4 major focus on children's drug production enterprises, performance

In recent years, with the liberalization of the second-born policy and the enhancement of children's awareness of drug safety, as well as the release of policies to encourage research and development of children's drugs, the domestic children's drug market has been expanding.
data show that in 2019, China's children's drug market size exceeded 150 billion yuan, the growth rate is higher than the overall growth rate of the pharmaceutical industry.
, but in the face of a hundred billion blue seas, it is not easy to find gold.
according to a survey by the National Federation of Industry and Commerce Pharmaceutical Chamber of Commerce, as of 2019, there are more than 6,000 pharmaceutical companies in China, only 10 specializing in the production of children's medicines, and only more than 30 enterprises in the children's drug production sector.
in the A-share market, more than 100 pharmaceutical companies, only Abao Pharmaceuticals, Kangzhi Pharmaceuticals, a mambo and Huluwa and other enterprises focused on the production of children's medicine.
, what is the current business situation of these four pharmaceutical companies? In its semi-annual results report released on the evening of August 25, Yabao Pharmaceuticals reported that net profit attributable to shareholders of listed companies in the first half of 2020 was about 61.04 million yuan, down 61.84 percent year-on-year, and operating income was about 1.152 billion yuan, down 26.78 percent year-on-year.
decline in the performance of the hospital is due to the impact of the epidemic, sales of terminal hospitals, chain pharmacies, primary clinics to reduce the number of patients led to a decline in sales.
2020 interim results report showed that first-half operating income of 411 million yuan, attributable to net profit of 7.4505 million yuan, an increase of 17.03 percent year-on-year.
In the first half of the special period, the company's half-year net profit can quickly achieve positive growth, mainly due to the beginning of 2018 around the development direction of children's health strategy ahead of the layout, focusing on the development of pharmaceutical production and sales sector at the same time, gradually expand the professional areas involved to better serve the public.
's 2020 mid-year report, released last year, showed operating income of 651 million yuan, down 15.82 percent year-on-year, and net profit attributable to shareholders of listed companies was 80.46 million yuan, down 24.98 percent year-on-year.
the decline in the company's revenue during the reporting period was mainly due to the decline in the number of visits to end-use medical facilities affected by the outbreak, and the impact of prevention and control measures on the company's market development plans.
, however, during the reporting period, the construction of a mas even-mast research and development team continued to grow, and the results of research and development were initially evident.
has undertaken more than 30 research and development projects and submitted 18 pharmaceutical (production) products, including 15 preparations and 3 raw materials, to the state regulatory authorities for approval or registration of pharmaceutical production.
, the company is also actively promoting high-end pharmaceutical preparation platform, pediatric pharmaceutical engineering laboratory and other research and development platform construction.
and accelerate the pace of research and development innovation, and actively promote diversified research and development model landing practice.
first half of 2020, Huluwa achieved revenue of 576 million yuan, down 5.77 percent year-on-year, and net profit of 42.51 million yuan, up 4.6 percent year-on-year.
reporting period, the company focused on promoting the following work, including: research and development, increase product research and development efforts, strengthen production and quality management, comprehensively ensure product quality, sales, the company continued to strengthen the construction of marketing network system, continue to standardize development, promote lean production, achieve fine production management, and further improve the level of enterprise management.
From the semi-annual reports of the four major children's pharmaceutical companies, the first half of the year by the impact of the special period, the number of hospitals, clinics, the number of patients decreased, many pharmaceutical enterprises received the impact of performance, but there are also in the face of adversity in accordance with the strategic layout of the steady progress to achieve net profit growth of enterprises.
, there are enterprises actively increase research and development investment.
industry believes that for companies focused on children's medicines, it is important to invest heavily in research and development if they are to take a share of the market in greater competition.
the development of children's pharmaceutical enterprises will not be a pick-up between the direction of research and development.